In the study of "Stroke prevention in atrial fibrillation: do we still need warfarin?" by Diener HC, Weber R, Lip GY, Hohnloser SH., posted in US National Library of Medicine National Institutes of Health, found that new anticoagulants add to the therapeutic options for patients with atrial fibrillation, and offer a number of advantages over warfarin, for both the clinician and patient, including a favourable bleeding profile and convenience of use. Consideration of these new anticoagulants will improve clinical decision making
Wednesday, December 7, 2011
Vitamin K antagonists
Posted by Chantel M. Contributed by US National Library of Medicine National Institutes of Health
In the study of "Stroke prevention in atrial fibrillation: do we still need warfarin?" by Diener HC, Weber R, Lip GY, Hohnloser SH., posted in US National Library of Medicine National Institutes of Health, found that new anticoagulants add to the therapeutic options for patients with atrial fibrillation, and offer a number of advantages over warfarin, for both the clinician and patient, including a favourable bleeding profile and convenience of use. Consideration of these new anticoagulants will improve clinical decision making
In the study of "Stroke prevention in atrial fibrillation: do we still need warfarin?" by Diener HC, Weber R, Lip GY, Hohnloser SH., posted in US National Library of Medicine National Institutes of Health, found that new anticoagulants add to the therapeutic options for patients with atrial fibrillation, and offer a number of advantages over warfarin, for both the clinician and patient, including a favourable bleeding profile and convenience of use. Consideration of these new anticoagulants will improve clinical decision making
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment